Improving the odds: ezetimibe and cardiovascular disease.

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading global cause of mortality.
• Cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is central to atherosclerosis.
• Statins are primary treatments for CVD, effectively lowering LDL-C.

Purpose of the Study:

• To evaluate the efficacy of additional therapies beyond statins for CVD.
• To assess treatments targeting residual risk factors like HDL-C and triglycerides.

Main Methods:

• Review of recent clinical trials investigating supplementary treatments for CVD.
• Comparison of outcomes for omega-3 fatty acids, fibrates, niacin, and CETP inhibitors against placebo in patients on statin therapy.

Main Results:

• Several trials explored additional treatments for CVD patients on statins.
• None of the investigated therapies demonstrated significant benefit over placebo when added to statin therapy.

Conclusions:

• Despite extensive research, achieving additional cardiovascular benefits beyond statin therapy remains a significant challenge.
• The concept that statins represent the peak of current atherosclerosis treatment efficacy persists.